Proquazone

Proquazone

SCHEMBL25341

Cc1ccc2c(-c3ccccc3)nc(=O)n(C(C)C)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 1.00
EGFR P00533 1/20 1.00
ADRA2A P08913 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
TBXA2R P21731 1/20 1.00
PTGS2 P35354 1/20 1.00
OPRD1 P41143 1/20 1.00
PDE4D Q08499 1/20 1.00
CASR P41180 13/20 0.58
LMNA P02545 2/20 0.44
PTGER1 P34995 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Proquazone SCHEMBL29508590 1.00 NR1I2 (1.00) NR1I2EGFRADRA2AADORA3TBXA2R
Proquazone SCHEMBL2931942 0.99 NR1I2 (0.97) NR1I2EGFRADRA2AADORA3TBXA2R
SCHEMBL11565990 0.92 NR1I2 (0.85) NR1I2EGFRADRA2AADORA3TBXA2R
Proquazone SCHEMBL11339177 0.89 NR1I2 (0.79) NR1I2EGFRADRA2AADORA3TBXA2R
SCHEMBL11723933 0.87 NR1I2 (0.77) NR1I2EGFRADRA2AADORA3TBXA2R
Fluproquazone SCHEMBL29363976 0.87 NR1I2 (0.77) NR1I2EGFRADRA2AADORA3TBXA2R
Fluproquazone SCHEMBL26210 0.87 NR1I2 (0.77) NR1I2EGFRADRA2AADORA3TBXA2R
SCHEMBL11605525 0.86 NR1I2 (0.76) NR1I2EGFRADRA2AADORA3TBXA2R
SCHEMBL11421197 0.85 NR1I2 (0.74) NR1I2EGFRADRA2AADORA3TBXA2R
SCHEMBL7680445 0.84 NR1I2 (0.72) NR1I2EGFRADRA2AADORA3TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 11218 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4742996-A1 SURGICAL CONSTRUCTS AND METHODS OF TISSUE FIXATION Arthrex Inc (US) 2026-05-20 EP claimed
EP-4719280-A1 ANTERIOR TIBIAL APPROACH FOR TOTAL ANKLE REPLACEMENT Arthrex, Inc. (US) 2026-04-08 EP claimed
EP-4661772-A2 ELASTIC SUTURES AND METHODS OF MAKING AND USE Arthrex, Inc. (US) 2025-12-17 EP claimed
WO-2025034353-A1 SURGICAL CONSTRUCTS AND METHODS OF TISSUE FIXATION ARTHREX, INC. (US) 2025-02-13 WO claimed
US-20250041208-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2025-02-06 US claimed
WO-2025006523-A1 ANTERIOR TIBIAL APPROACH FOR TOTAL ANKLE REPLACEMENT ARTHREX, INC. (US) 2025-01-02 WO claimed
EP-4444277-A1 NEW INJECTABLE COMBINATION FORMULATION Nanexa AB (SE) 2024-10-16 EP claimed
WO-2024196904-A2 ELASTIC SUTURES AND METHODS OF MAKING AND USE ARTHREX, INC. (US) 2024-09-26 WO claimed
WO-2024105529-A1 CHEMICAL DISBUDDING OF LIVESTOCK MASSEY UNIVERSITY (NZ) 2024-05-23 WO claimed
EP-4335413-A2 PROSTHETIC TISSUE VALVES Cormatrix Cardiovascular, Inc. (US) 2024-03-13 EP claimed
EP-0644755-A1 SURFACE MODIFIED NSAID NANOPARTICLES. EASTMAN KODAK CO (US) 1995-03-29 EP claimed
WO-1993025190-A1 SURFACE MODIFIED NSAID NANOPARTICLES EASTMAN KODAK COMPANY (US) 1993-12-23 WO claimed
EP-0111456-B1 ANALGESIC COMBINATIONS Cooper, Stephen A. Dr. (US) 1989-07-12 EP claimed
EP-0028410-B1 USE OF THROMBOXANE-SYNTHETASE INHIBITING COMPOUNDS IN THE TREATMENT OF OBESITY AND THE LOWERING OF INSULIN LEVELS F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1987-09-30 EP claimed
WO-1984002273-A1 ANALGESIC COMBINATIONS SANDOZ AG (CH) 1984-06-21 WO claimed
EP-0111456-A1 Analgesic combinations Cooper, Stephen A. Dr. (US) 1984-06-20 EP claimed
US-4442084-A ABSORPTION, LIQUID PHASE CLAUS PROCESS, RECYCLING SANDOZ LTD. (CH) 1984-04-10 US claimed
EP-0028410-A1 Use of thromboxane-synthetase inhibiting compounds in the treatment of obesity and the lowering of insulin levels F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-05-13 EP claimed
US-4236006-A Preparation of quinazolin-2(1H)-ones SANDOZ LTD. (CH) 1980-11-25 US claimed
US-4224328-A Methods with 1-substituted-4-aryl-quinazolin-2(1H)-ones and thiones and pyrido[2,3-d]pyrimidin-2-ones as platelet aggregation inhibitors SANDOZ, INC. (US) 1980-09-23 US claimed